High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina

Experimental Eye Research

Volumn 107, Issue , 2013, Pages 101-109

  Mohammad, Ghulam ^a   Siddiquei, Mohammad Mairaj ^a   Othman, Amira ^b   Al Shabrawey, Mohamed ^b   Abu El Asrar, Ahmed M ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Diabetes; HMGB 1; Inflammation; RAGE; Retina; Vascular permeability

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCCLUDIN; RECOMBINANT HIGH MOBILITY GROUP B1 PROTEIN; RECOMBINANT PROTEIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL FUNCTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRICAL CELL SUBSTRATE IMPEDANCE SENSING SYSTEM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IMPEDANCE; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RETINA; RETINA BLOOD VESSEL; RETINA ENDOTHELIAL CELL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRIC IMPEDANCE; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTERCELLULAR ADHESION MOLECULE-1; INTRAVITREAL INJECTIONS; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; OCCLUDIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 84871965375     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.12.009     Document Type: Article

References (56)

1. Adamis A.P. Is diabetic retinopathy an inflammatory disease?. Br. J. Ophthalmol. 2002, 86:363-365.
2. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H., Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000, 192:565-570.
3. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998, 47:1953-1959.
4. Barber A.J., Antonetti D.A., Gardner T.W. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest. Ophthalmol. Vis. Sci. 2000, 41:3561-3568.
5. Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 2004, 84:869-901.
6. Behzadian M.A., Wang X.L., Al-Shabrawey M., Caldwell R.B. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 1998, 24:216-225.
7. El-Asrar A.M. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr. J. Ophthalmol. 2012, 19:70-74.
8. El-Asrar A.M., Nawaz M.I., Kangave D., Geboes K., Ola M.S., Ahmad S., Al-Shabrawey M. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol. Vis. 2011, 17:1829-1838.
9. El-Asrar A.M., Missotten L., Geboes K. Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Mol. Vis. 2011, 17:508-518.
10. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
11. Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S.A., Tsukita S.H. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell. Biol. 1993, 123:1777-1788.
12. Gong G., Yuan L.B., Hu L., Wu W., Yin L., Hou J.L., Liu Y.H., Zhou L.S. Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacol. Sin. 2012, 33(1):11-18. 10.1038/aps.2011.151.
13. Hirase T., Staddon J.M., Saitou M., Ando-Akatsuka Y., Itoh M., Furuse M., Fujimoto K., Tsukita S., Rubin L.L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell. Sci. 1997, 110(Pt 14):1603-1613.
14. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S., Hida T., Oguchi Y., Adamis A.P. VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 2003, 44:2155-2162.
15. Kaji Y., Usui T., Ishida S., Yamashiro K., Moore T.C., Moore J., Yamamoto Y., Yamamoto H., Adamis A.P. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest. Ophthalmol. Vis. Sci. 2007, 48:858-865.
16. Kim J., Sohn E., Kim C.S., Jo K., Kim J.S. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am. J. Nephrol. 2011, 33:524-529.
17. Kim S.W., Jin Y., Shin J.H., Kim I.D., Lee H.K., Park S., Han P.L., Lee J.K. Glycyrrhizic acid affords robust neuroprotection in the postischemic brainvia anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol. Dis. 2012, 46(1):147-156.
18. Kokkola R., Sundberg E., Ulfgren A.K., Palmblad K., Li J., Wang H., Ulloa L., Yang H., Yan X.J., Furie R., Chiorazzi N., Tracey K.J., Andersson U., Harris H.E. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002, 46:2598-2603.
19. Kowluru R.A., Koppolu P., Chakrabarti S., Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic. Res. 2003, 37:1169-1180.
20. Krady J.K., Basu A., Allen C.M., Xu Y., LaNoue K.F., Gardner T.W., Levison S.W. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54:1559-1565.
21. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
22. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5:331-342.
23. Luan Z.G., Zhang H., Yang P.T., Ma X.C., Zhang C., Guo R.X. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Immunobiology 2010, 215:956-962.
24. Mitola S., Belleri M., Urbinati C., Coltrini D., Sparatore B., Pedrazzi M., Melloni E., Presta M. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J. Immunol. 2006, 176:12-15.
25. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., Aiello L.P., Ogura Y., Adamis A.P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy viaintercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10836-10841.
26. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 1996, 97:2883-2890.
27. Mohammad G., Kowluru R.A. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:3832-3841.
28. Mohammad G., Kowluru R.A. Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. J. Cell. Physiol. 2012, 227:1052-1061.
29. Mollica L., De Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., Agresti A., Trisciuoglio L., Musco G., Bianchi M.E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 2007, 14(4):431-441.
30. Muranaka K., Yanagi Y., Tamaki Y., Usui T., Kubota N., Iriyama A., Terauchi Y., Kadowaki T., Araie M. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest. Ophthalmol. Vis. Sci. 2006, 47:4547-4552.
31. Ni H., Yan X., Lin Z., Jin X. High glucose may decrease the innate immune through TLRs in cornea epithelium. Mol. Vis. 2011, 17:3384-3391.
32. Nin J.W., Ferreira I., Schalkwijk C.G., Prins M.H., Chaturvedi N., Fuller J.H., Stehouwer C.D. Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Eur. J. Endocrinol 2012, 166(2):325-332.
33. Nogueira-Machado J.A., Volpe C.M., Veloso C.A., Chaves M.M. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin. Ther. Targets 2011, 15:1023-1035.
34. Ohnishi M., Katsuki H., Fukutomi C., Takahashi M., Motomura M., Fukunaga M., Matsuoka Y., Isohama Y., Izumi Y., Kume T., Inoue A., Akaike A. HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology 2011, 61(5-6):975-980.
35. Oshitari T., Polewski P., Chadda M., Li A.F., Sato T., Roy S. Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes 2006, 55:86-92.
36. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., Choe K.H., Strassheim D., Pitts T.M., Tracey K.J., Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell. Physiol. 2003, 284:C870-C879.
37. Rogers R.A., Lynch R.D., Schneeberger E.E. Occludin is a functional component of the tight junction. J. Cell. Sci. 1996, 109:2287-2298.
38. Roy S., Nasser S., Yee M., Graves D.T., Roy S. A long term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats. Mol. Vis. 2011, 17:3166-3174.
39. Roy S., Sato T., Paryani G., Kao R. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 2003, 52:1229-1234.
40. Sato H., Goto W., Yamamura J., Kurokawa M., Kageyama S., Takahara T., Watanabe A., Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antivir. Res. 1996, 30(2-3):171-177.
41. Sitia G., Iannacone M., Müller S., Bianchi M.E., Guidotti L.G. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J. Leukoc. Biol. 2007, 81(1):100-107.
42. Schlueter C., Weber H., Meyer B., Rogalla P., Röser K., Hauke S., Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 2005, 166:1259-1263.
43. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 1997, 150:523-531.
44. Tang D., Kang R., Zeh H.J., Lotze M.T. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010, 1799:131-140.
45. Tavelin S., Hashimoto K., Malkinson J., Lazorova L., Toth I., Artursson P. A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol. 2003, 64:1530-1540.
46. Treutiger C.J., Mullins G.E., Johansson A.S., Rouhiainen A., Rauvala H.M., Erlandsson-Harris H., Andersson U., Yang H., Tracey K.J., Andersson J., Palmblad J.E. High mobility group 1 B-box mediates activation of human endothelium. J. Intern. Med. 2003, 254:375-385.
47. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., Czura C.J., Fink M.P., Tracey K.J. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12351-12356.
48. van Beijnum J.R., Buurman W.A., Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99.
49. Voll R.E., Urbonaviciute V., Herrmann M., Kalden J.R. High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases. Isr. Med. Assoc. J. 2008, 10:26-28.
50. Volz H.C., Seidel C., Laohachewin D., Kaya Z., Müller O.J., Pleger S.T., Lasitschka F., Bianchi M.E., Remppis A., Bierhaus A., Katus H.A., Andrassy M. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol. 2010, 105:805-820.
51. Wang H., Vishnubhakat J.M., Bloom O., Zhang M., Ombrellino M., Sama A., Tracey K.J. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392.
52. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Adnersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
53. Yamada S., Maruyama I. HMGB1, a novel infl{ligature}ammatory cytokine. Clin. Chim. Acta 2007, 375:36-42.
54. Yamashiro K., Tsujikawa A., Ishida S., Usui T., Kaji Y., Honda Y., Ogura Y., Adamis A.P. Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am. J. Pathol. 2003, 163:253-259.
55. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255.
56. Yeh C.H., Sturgis L., Haidacher J., Zhang X.N., Sherwood S.J., Bjercke R.J., Juhasz O., Crow M.T., Tilton R.G., Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappa B transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.